

## Guidelines for abstract submission early career scientists

ECNP Workshop 2019  
7-10 March 2019, Nice, France

### 1. GUIDELINES


Abstracts should be prepared strictly according to the following instructions:

#### Content

- Abstracts should include:
  - brief introduction to the research question
  - aim(s) of the study
  - methods used including statistical analysis methods
  - summary of results containing real data and the outcome of statistical analyses
  - conclusions
- Abstracts must report on high quality original research in the field of neuropsychopharmacology that has not been published whole or in part elsewhere.
- Abstracts must be relevant to one of the four main topics.
- The statements, in particular in the conclusion section, should be balanced.
- No abbreviations or trade names are allowed in the title. However, the generic name may be used.
- Use standard abbreviations for well established neuropsychopharmaceuticals. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all neuropsychopharmaceuticals used.
- A disclosure on potential conflicts of interest is requested when submitting an abstract.

#### Layout

- Abstracts must be submitted in English.
- Type the abstract text in single spacing.
- The title should not exceed two lines (approximately 120 characters and/or 20 words).
- Write the title in lower case letters and do not put a dot at the end.
- Abstracts should have a minimum of 450 and a maximum of 500 words.
- The use of underlined is not permitted. Words that need emphasis should be **bold** or *italics* type.
- Only one table is allowed, please note that graphs and pictures can not be included. Tables cannot be

inserted with copy/paste. Please type your table with the help of the 'table button' .

#### References

- No more than five references to previous publications may be included. In the body text, a publication should be referred to by a consecutive number between brackets, i.e. [1], [2], [3], [4] and [5].
- Authors are responsible for the accuracy of references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the text.
- The references should be provided in accordance with the following examples:

##### *Reference to a journal publication*

[1] Chamberlain, S.R., Hampshire, A., Muller, U., Rubia, K., Del Campo, N., 2009. Atomoxetine modulates right inferior frontal activation during inhibitory control. A pharmacological functional magnetic resonance imaging study. *Biol Psychiatry* 65, 550-555.

#### Reference to a (chapter in a) book

[1] Williams, K., 1980. Pharmacological dilemmas in psychiatry, in: Weaver, R., Smith, L.K., Perspective on psychiatry, second ed. Theme Press, Cornwall, pp. 301-315.

#### Reference to a website

[1] McArthur, J., 2014. The link between schizophrenia and dementia, a new perspective. Available from: [www.biopsychiatry.com/schizophrenia-dementia](http://www.biopsychiatry.com/schizophrenia-dementia). [Accessed: 12 May 2015].

#### Reference to a DOI

[1] De Jong, A., 2015. Developments in the field of neuropsychopharmacology. Pharm. Journal, <http://dx.doi.org/10.2215.j.pharmjournal.2014.09.003>.

## Subtopics

Please select a minimum of two and a maximum of three subtopics from the [list of subtopics](#). A subtopics index will be published in the workshop supplement to the journal *European Neuropsychopharmacology*.

## Authors

- Insert the author's first name and last name and address(es) of the institution as indicated on the on-line form. Do not add: Prof, Dr, etc. and do not use initials
- State your name as the author who will present the poster (first author).

## 2. REVIEW AND PUBLICATION

### Review

An abstract is eligible for review when the abstract is submitted according to the guidelines and on or before the deadline.

All submitted abstracts will be evaluated by a scientific review committee. The author will be informed of the committee's decision by e-mail no later than 20 December 2018. There can be no correspondence about the outcome.

When your abstract is accepted you will have to give a poster presentation on this abstract at the ECNP Workshop and attend all the sessions from Thursday late afternoon until Sunday 12.35 hours.

From the accepted abstracts, 20 early career scientists will be invited to present their data during one of the main sessions at the ECNP Workshop 2019.

### Publication

The abstracts will be reviewed according to the scientific standard of the journal *European Neuropsychopharmacology* and all accepted abstracts will be published in a supplement to the journal. The publisher of *European Neuropsychopharmacology* holds all publication rights including copyright.

After the workshop, ECNP will publish all posters on the website [www.ecnp.eu](http://www.ecnp.eu). If you do not wish to have your poster published on the website, please tick the appropriate box when submitting your abstract.

**Abstracts should be received on or before 17 October 2018, 17.00 CET – Central European Time**